Burning Rock Biotech Limited (NASDAQ:BNR - Get Free Report) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totalling 60,500 shares, a decline of 6.6% from the December 15th total of 64,800 shares. Based on an average daily volume of 26,300 shares, the short-interest ratio is presently 2.3 days. Currently, 0.7% of the shares of the stock are sold short.
Hedge Funds Weigh In On Burning Rock Biotech
An institutional investor recently bought a new position in Burning Rock Biotech stock. SkyView Investment Advisors LLC purchased a new position in shares of Burning Rock Biotech Limited (NASDAQ:BNR - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,000 shares of the company's stock, valued at approximately $64,000. SkyView Investment Advisors LLC owned 0.10% of Burning Rock Biotech as of its most recent filing with the Securities and Exchange Commission (SEC). 30.03% of the stock is owned by institutional investors.
Burning Rock Biotech Price Performance
Shares of BNR traded up $0.25 during mid-day trading on Friday, hitting $6.75. The company's stock had a trading volume of 308 shares, compared to its average volume of 7,089. Burning Rock Biotech has a fifty-two week low of $2.62 and a fifty-two week high of $9.80. The stock has a market capitalization of $69.07 million, a price-to-earnings ratio of -2.25 and a beta of 0.55. The firm has a 50-day moving average price of $6.15 and a 200 day moving average price of $5.29.
About Burning Rock Biotech
(
Get Free Report)
Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Burning Rock Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Burning Rock Biotech wasn't on the list.
While Burning Rock Biotech currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
